Cancer type-specific adverse events of immune checkpoint inhibitors: A systematic review and meta-analysis.

ABSTRACT:

Background

The distribution of adverse events (AEs) triggered by immune checkpoint inhibitors (ICIs) across different cancer types has never been demonstrated.

Methods

Randomised controlled trials exclusively assessing ICI monotherapy in cohorts of over 100 patients were considered. Our primary outcome was a comprehensive summary of the distribution of all-grade treatment-related adverse events (TRAEs) as well as serious TRAEs (CTCAE grade 3 or higher) across different malignancies. The study is registered with PROSPERO CRD42023387934.

Findings

75 trials that enrolled over 100 patients were included. While investigating the incidence of each TRAE across various cancers, we found special linkages existed between certain TRAEs and particular cancer types. In anti-PD-1 m

SUBMITTER: Tong X 

PROVIDER: S-EPMC11757769 | biostudies-literature | 2025 Jan

REPOSITORIES: biostudies-literature